Kirkstall Limited, a subsidiary of Imaging Biometrics Ltd, received funding from BBSRC and NC3Rs to develop a microfluidic 'tumour on a chip' model for glioblastoma, the most aggressive adult brain cancer. This model will simulate the blood-brain barrier and tumour environment using human-derived cells to improve drug testing accuracy, overcoming limitations of animal models. The project, in collaboration with Nottingham Trent University, aims to enhance glioblastoma treatment development by enabling better study of drug penetration and tumour growth. Imaging Biometrics CEO highlighted the synergy with their MRI analysis software, potentially transforming glioblastoma research.
Photronics, Inc. is under investigation by Glancy Prongay Wolke & Rotter LLP for possible securities law violations following its Q2 2026 earnings report. The company reported a revenue decline to $209 million and a drop in operating margins to 20.1%...
Shell plc announced that as of May 29, 2026, it has 5,586,155,889 ordinary shares outstanding, each with a nominal value of €0.07. The company holds no shares in treasury, and this figure includes shares bought back but not yet cancelled under its sh...
Aduro Clean Technologies announced its participation in several major industry and investor conferences in June 2026, including events in London, Toronto, Frankfurt, and Pittsburgh. The company will showcase its Hydrochemolytic™ Technology and discus...
Aduro Clean Technologies announced its participation in several investor and industry conferences in June 2026, including events in London, Toronto, Frankfurt, and Pittsburgh. The company will showcase its Hydrochemolytic™ technology, discuss progres...
After Palantir's Q1 earnings report, analysts sharply disagree on its valuation, with price targets ranging from $90 to $230. The divide reflects contrasting views on Palantir's AI software platform and growth potential. Bulls see durable government ...
